Coverart for item
The Resource Antibody-drug conjugates, edited by Laurent Ducry

Antibody-drug conjugates, edited by Laurent Ducry

Label
Antibody-drug conjugates
Title
Antibody-drug conjugates
Statement of responsibility
edited by Laurent Ducry
Contributor
Editor
Subject
Genre
Language
eng
Summary
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future
Member of
Cataloging source
GW5XE
Dewey number
615.3/7
Illustrations
illustrations
Index
index present
Language note
English
LC call number
RS201.A56
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
  • W1
  • QW 575.5.A6
NLM item number
ME9616J v.1045 2013
http://library.link/vocab/relatedWorkOrContributorName
Ducry, Laurent
Series statement
Methods in Molecular Biology,
Series volume
1045
http://library.link/vocab/subjectName
  • Antibody-drug conjugates
  • Antibody-toxin conjugates
  • Immunoglobulins
  • Disease
  • Therapeutic Uses
  • Immunoproteins
  • Pharmacologic Actions
  • Chemical Actions and Uses
  • Serum Globulins
  • Blood Proteins
  • Globulins
  • Proteins
  • Amino Acids, Peptides, and Proteins
  • Neoplasms
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Antibodies
  • Immunoconjugates
  • Drug Combinations
  • Pharmaceutical Preparations
  • Antibody-drug conjugates
  • Antibody-toxin conjugates
  • Biology
  • Health & Biological Sciences
  • Microbiology & Immunology
Label
Antibody-drug conjugates, edited by Laurent Ducry
Instantiates
Publication
Note
Includes index
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review -- Antibody-Drug Conjugate Target Selection: Critical Factors -- Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization -- Antibody-Drug Conjugate Payloads -- Linker Technologies for Antibody-Drug Conjugates -- In Vivo Testing of Drug-Linker Stability -- Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates -- Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment -- Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting -- Protocols for Lysine Conjugation -- Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers -- Enzymatic Antibody Modification by Bacterial Transglutaminase -- Formulation Development of Antibody-Drug Conjugates -- Conjugation Process Development and Scale-Up -- Methods for Conjugating Antibodies to Nanocarriers -- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy -- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography -- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS -- Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF -- Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)
Control code
857143002
Dimensions
unknown
Extent
1 online resource (x, 317 pages)
File format
unknown
Form of item
online
Isbn
9781627035408
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other control number
10.1007/978-1-62703-541-5
Other physical details
illustrations.
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)857143002
Label
Antibody-drug conjugates, edited by Laurent Ducry
Publication
Note
Includes index
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review -- Antibody-Drug Conjugate Target Selection: Critical Factors -- Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization -- Antibody-Drug Conjugate Payloads -- Linker Technologies for Antibody-Drug Conjugates -- In Vivo Testing of Drug-Linker Stability -- Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates -- Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment -- Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting -- Protocols for Lysine Conjugation -- Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers -- Enzymatic Antibody Modification by Bacterial Transglutaminase -- Formulation Development of Antibody-Drug Conjugates -- Conjugation Process Development and Scale-Up -- Methods for Conjugating Antibodies to Nanocarriers -- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy -- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography -- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS -- Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF -- Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)
Control code
857143002
Dimensions
unknown
Extent
1 online resource (x, 317 pages)
File format
unknown
Form of item
online
Isbn
9781627035408
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other control number
10.1007/978-1-62703-541-5
Other physical details
illustrations.
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
(OCoLC)857143002

Library Locations

    • Ellis LibraryBorrow it
      1020 Lowry Street, Columbia, MO, 65201, US
      38.944491 -92.326012
Processing Feedback ...